Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Azd-9833
2. Azd9833
3. N-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo(4,3-f)isoquinolin-6-yl)pyridin-3-amine
1. Azd-9833
2. Unii-jup57a8epz
3. Azd9833
4. 2222844-89-3
5. Camizestrant [usan]
6. Jup57a8epz
7. Az14066724
8. Az-14066724
9. N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine
10. 3-pyridinamine, N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-6,7,8,9-tetrahydro-8-methyl-7-(2,2,2-trifluoroethyl)-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-
11. Camizestrant [inn]
12. Camizestrant [who-dd]
13. Chembl4650365
14. Schembl20089710
15. Ex-a5025
16. Nsc828717
17. Who 11592
18. At22885
19. Nsc-828717
20. Hy-136255
21. Cs-0121043
22. N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-3-pyridinamine
23. N-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine
| Molecular Weight | 476.5 g/mol |
|---|---|
| Molecular Formula | C24H28F4N6 |
| XLogP3 | 4.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 7 |
| Exact Mass | 476.23115757 g/mol |
| Monoisotopic Mass | 476.23115757 g/mol |
| Topological Polar Surface Area | 60.1 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 674 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Camizestrant (AZD9833) is a potent, next-generation oral SERD and pure ERα antagonist, that has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations.
Lead Product(s): Camizestrant,Palbociclib,Luteinizing Hormone
Therapeutic Area: Oncology Brand Name: AZD9833
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Lead Product(s) : Camizestrant,Palbociclib,Luteinizing Hormone
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Camizestrant (AZD9833) is a potent, next-generation oral SERD and pure ERα antagonist, that has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations.
Brand Name : AZD9833
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 08, 2022
Details:
AZD9833 (camizestrant) is a potent, next-generation oral SERD and pure ERα antagonist, that has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations.
Lead Product(s): Camizestrant
Therapeutic Area: Oncology Brand Name: AZD9833
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Lead Product(s) : Camizestrant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERE...
Details : AZD9833 (camizestrant) is a potent, next-generation oral SERD and pure ERα antagonist, that has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations.
Brand Name : AZD9833
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 26, 2022
Details:
New data from the SERENA-1 Phase I trial show strong efficacy and safety profile for next-generation oral SERD AZD9833 in HR-positive advanced breast cancer.
Lead Product(s): Camizestrant,Palbociclib
Therapeutic Area: Oncology Brand Name: AZD9833
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Lead Product(s) : Camizestrant,Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : New data from the SERENA-1 Phase I trial show strong efficacy and safety profile for next-generation oral SERD AZD9833 in HR-positive advanced breast cancer.
Brand Name : AZD9833
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
